Search Results - "Fang, James C"

Gastrointestinal and Liver Issues in Heart Failure by Sundaram, Varun, Fang, James C

“…Heart failure affects ≈23 million people worldwide and continues to have a high mortality despite advancements in modern pharmacotherapy and device therapy. HF…”
Get full text

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines by Heidenreich, Paul A., Bozkurt, Biykem, Aguilar, David, Allen, Larry A., Byun, Joni J., Colvin, Monica M., Deswal, Anita, Drazner, Mark H., Dunlay, Shannon M., Evers, Linda R., Fang, James C., Fedson, Savitri E., Fonarow, Gregg C., Hayek, Salim S., Hernandez, Adrian F., Khazanie, Prateeti, Kittleson, Michelle M., Lee, Christopher S., Link, Mark S., Milano, Carmelo A., Nnacheta, Lorraine C., Sandhu, Alexander T., Stevenson, Lynne Warner, Vardeny, Orly, Vest, Amanda R., Yancy, Clyde W.

“…The "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" replaces the "2013 ACCF/AHA Guideline for the Management of Heart Failure" and the "2017…”
Get full text

Rise of the Machines — Left Ventricular Assist Devices as Permanent Therapy for Advanced Heart Failure by Fang, James C

“…Traditionally, the only definitive therapy for patients who have advanced, medically refractory heart failure was replacement of the heart with another human…”
Get full text

Cardiac Recovery During Long-Term Left Ventricular Assist Device Support by Wever-Pinzon, Omar, MD, Drakos, Stavros G., MD, PhD, McKellar, Stephen H., MD, MSc, Horne, Benjamin D., MPH, PhD, Caine, William T., MD, Kfoury, Abdallah G., MD, Li, Dean Y., MD, PhD, Fang, James C., MD, Stehlik, Josef, MD, MPH, Selzman, Craig H., MD

“…Abstract Background The number of centers with left ventricular assist device (LVAD) research programs focused on cardiac recovery is very small. Therefore,…”
Get full text

Thyroid Dysfunction in Heart Failure and Cardiovascular Outcomes by Kannan, Lakshmi, Shaw, Pamela A, Morley, Michael P, Brandimarto, Jeffrey, Fang, James C, Sweitzer, Nancy K, Cappola, Thomas P, Cappola, Anne R

“…The effects of thyroid dysfunction in patients with preexisting heart failure have not been adequately studied. We examined the prevalence of thyroid…”
Get full text

The frailty syndrome and outcomes in the TOPCAT trial by Sanders, Natalie A., Supiano, Mark A., Lewis, Eldrin F., Liu, Jiankang, Claggett, Brian, Pfeffer, Marc A., Desai, Akshay S., Sweitzer, Nancy K., Solomon, Scott D., Fang, James C.

“…Aims The impact of frailty on outcomes in randomized heart failure with preserved ejection fraction (HFpEF) trials has not been previously reported. This…”
Get full text

Ventricular-Arterial Coupling, Remodeling, and Prognosis in Chronic Heart Failure by Ky, Bonnie, MD, MSCE, French, Benjamin, PhD, May Khan, Abigail, MD, Plappert, Ted, CVT, Wang, Andrew, BA, Chirinos, Julio A., MD, Fang, James C., MD, Sweitzer, Nancy K., MD, PhD, Borlaug, Barry A., MD, Kass, David A., MD, St. John Sutton, Martin, MBBS, Cappola, Thomas P., MD, ScM

“…Objectives The objective of this study was to compare the physiological determinants of ejection fraction (EF)—ventricular size, contractile function, and…”
Get full text

Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials by Sipahi, Ilke, Dr, Debanne, Sara M, PhD, Rowland, Douglas Y, PhD, Simon, Daniel I, MD, Fang, James C, MD

“…Summary Background Angiotensin-receptor blockers (ARBs) are a widely used drug class approved for treatment of hypertension, heart failure, diabetic…”
Get full text

Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: Meta-analysis of randomized controlled trials by Sipahi, Ilke, MD, Chou, Josephine C., MD, Hyden, Marshall, MD, Rowland, Douglas Y., PhD, Simon, Daniel I., MD, Fang, James C., MD

“…Background Cardiac resynchronization therapy (CRT) is effective in reducing clinical events in systolic heart failure patients with a wide QRS. Previous…”
Get full text

World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation by Fang, James C., MD, DeMarco, Teresa, MD, Givertz, Michael M., MD, Borlaug, Barry A., MD, Lewis, Gregory D., MD, Rame, J. Eduardo, MD, Mphil, Gomberg-Maitland, Mardi, MD, MSc, Murali, Srinivas, MD, Frantz, Robert P., MD, McGlothlin, Dana, MD, Horn, Evelyn M., MD, Benza, Raymond L., MD

“…Pulmonary hypertension associated with left heart disease is the most common form of pulmonary hypertension encountered in clinical practice today. Although…”
Get full text

Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) by Hegde, Sheila M, Claggett, Brian, Shah, Amil M, Lewis, Eldrin F, Anand, Inder, Shah, Sanjiv J, Sweitzer, Nancy K, Fang, James C, Pitt, Bertram, Pfeffer, Marc A, Solomon, Scott D

“…Physical activity (PA) is inversely associated with adverse cardiovascular outcomes in healthy populations, but the impact of physical activity in patients…”
Get full text

Right Heart Catheterization in Cardiogenic Shock Is Associated With Improved Outcomes: Insights From the Nationwide Readmissions Database by Ranka, Sagar, Mastoris, Ioannis, Kapur, Navin K, Tedford, Ryan J, Rali, Aniket, Acharya, Prakash, Weidling, Robert, Goyal, Amandeep, Sauer, Andrew J, Gupta, Bhanu, Haglund, Nicholas, Gupta, Kamal, Fang, James C, Lindenfeld, JoAnn, Shah, Zubair

“…Background The usefulness of right heart catherization (RHC) has long been debated, and thus, we aimed to study the real-world impact of the use of RHC in…”
Get full text

Impact of Ischemic Heart Failure Etiology on Cardiac Recovery During Mechanical Unloading by Wever-Pinzon, James, MD, Selzman, Craig H., MD, Stoddard, Greg, MPH, MBA, Wever-Pinzon, Omar, MD, Catino, Anna, MD, Kfoury, Abdallah G., MD, Diakos, Nikolaos A., MD, Reid, Bruce B., MD, McKellar, Stephen, MD, Bonios, Michael, MD, PhD, Koliopoulou, Antigone, MD, Budge, Deborah, MD, Kelkhoff, Aaron, MD, Stehlik, Josef, MD, Fang, James C., MD, Drakos, Stavros G., MD, PhD

“…Abstract Background Small-scale studies focused mainly on nonischemic cardiomyopathy (NICM) have shown that a subset of left ventricular assist device (LVAD)…”
Get full text

Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure by Costanzo, Maria Rosa, MD, FACC, Guglin, Maya E., MD, FACC, Saltzberg, Mitchell T., MD, FACC, Jessup, Mariell L., MD, FACC, Bart, Bradley A., MD, FACC, Teerlink, John R., MD, FACC, Jaski, Brian E., MD, FACC, Fang, James C., MD, FACC, Feller, Erika D., MD, FACC, Haas, Garrie J., MD, FACC, Anderson, Allen S., MD, FACC, Schollmeyer, Michael P., DVM, Sobotka, Paul A., MD, FACC

“…Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure Maria Rosa Costanzo, Maya E. Guglin, Mitchell T…”
Get full text

High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure by Ky, Bonnie, French, Benjamin, McCloskey, Kristin, Rame, J Eduardo, McIntosh, Erin, Shahi, Puja, Dries, Daniel L, Tang, W H Wilson, Wu, Alan H B, Fang, James C, Boxer, Rebecca, Sweitzer, Nancy K, Levy, Wayne C, Goldberg, Lee R, Jessup, Mariell, Cappola, Thomas P

“…Soluble ST2 reflects activity of an interleukin-33-dependent cardioprotective signaling axis and is a diagnostic and prognostic marker in acute heart failure…”
Get full text

Myocardial Atrophy and Chronic Mechanical Unloading of the Failing Human Heart by Diakos, Nikolaos A., MD, Selzman, Craig H., MD, Sachse, Frank B., PhD, Stehlik, Josef, MD, Kfoury, Abdallah G., MD, Wever-Pinzon, Omar, MD, Catino, Anna, MD, Alharethi, Rami, MD, Reid, Bruce B., MD, Miller, Dylan V., MD, Salama, Mohamed, MD, Zaitsev, Alexey V., PhD, Shibayama, Junko, PhD, Li, Hui, MD, Fang, James C., MD, Li, Dean Y., MD, PhD, Drakos, Stavros G., MD, PhD

“…Abstract Background In animal models of heterotopic transplantation, mechanical unloading of the normal, nonhypertrophic heart results in atrophy. Primarily on…”
Get full text

Multiple biomarkers for risk prediction in chronic heart failure by Ky, Bonnie, French, Benjamin, Levy, Wayne C, Sweitzer, Nancy K, Fang, James C, Wu, Alan H B, Goldberg, Lee R, Jessup, Mariell, Cappola, Thomas P

“…Prior studies have suggested using a panel of biomarkers that measure diverse biological processes as a prognostic tool in chronic heart failure. Whether this…”
Get full text

Trends and Outcomes of Cardiogenic Shock in Patients With End-Stage Renal Disease: Insights From USRDS Database by Dalia, Tarun, Pothuru, Suveenkrishna, Chan, Wan-Chi, Mehta, Harsh, Goyal, Amandeep, Farhoud, Hassan, Boda, Ilham, Malhotra, Anureet, Vidic, Andrija, Rali, Aniket S, Hanff, Thomas C, Gupta, Kamal, Fang, James C, Shah, Zubair

“…There is a paucity of data regarding epidemiology, temporal trends, and outcomes of patients with cardiogenic shock (CS) and end-stage renal disease (chronic…”
Get full text

Immunologic effects of continuous-flow left ventricular assist devices before and after heart transplant by Ko, Byung-Soo, Drakos, Stavros, Kfoury, Abdallah G, Hurst, Denise, Stoddard, Gregory J, Willis, Carrie A, Delgado, Julio C, Hammond, Elizabeth H, Gilbert, Edward M, Alharethi, Rami, Revelo, Monica P, Nativi-Nicolau, Jose, Reid, Bruce B, McKellar, Stephen H, Wever-Pinzon, Omar, Miller, Dylan V, Eckels, David D, Fang, James C, Selzman, Craig H, Stehlik, Josef

“…Background Immune allosensitization can be triggered by continuous-flow left ventricular assist devices (CF LVAD). However, the effect of this type of…”
Get full text

Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure by French, Benjamin, PhD, Wang, Le, MS, Ky, Bonnie, MD, MSCE, Brandimarto, Jeffrey, MS, Basuray, Anupam, MD, MPH, Fang, James C., MD, Sweitzer, Nancy K., MD, PhD, Cappola, Thomas P., MD, ScM

“…Highlights • Age, symptoms of heart failure, and renal function affected galectin-3 levels. • Galectin-3 was strongly associated with adverse terminal outcomes…”
Get full text